Adalimumab
- Generic Name
- Adalimumab
- Brand Names
- Amjevita, Cyltezo, Humira, Hyrimoz, Yusimry, Hulio, Hefiya, Libmyris, Imraldi, Amsparity, Idacio, Hukyndra, Amgevita, Yuflyma
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 331731-18-1
- Unique Ingredient Identifier
- FYS6T7F842
- Background
Adalimumab is a subcutaneously administered biological disease modifier for the treatment of rheumatoid arthritis and other chronic debilitating diseases mediated by tumor necrosis factor. It was originally launched by Abbvie in the U.S. and approved in 2002 by the FDA. This drug is frequently known as Humira. It is produced by recombinant DNA technology usi...
- Indication
Adalimumab is indicated for the following conditions:
Adalimumab has also been used off-label to treat Pyoderma gangrenosum.
- Associated Conditions
- Ankylosing Spondylitis (AS), Hidradenitis Suppurativa (HS), Moderate to Severe Chronic Plaque Psoriasis, Moderate to Severe Rheumatoid Arthritis, Moderately to Severely Active Crohn's Disease, Moderately to Severely Active Ulcerative Colitis, Non-infectious Intermediate, Posterior and Panuveitis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Pyoderma Gangrenosum
- Associated Therapies
- -
Adalimumab Drug Optimisation in Rheumatoid Arthritis Using Therapeutic Drug Monitoring
- Conditions
- Interventions
- First Posted Date
- 2019-12-11
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Reade Rheumatology Research Institute
- Target Recruit Count
- 267
- Registration Number
- NCT04194827
- Locations
- 🇳🇱
Reade Rheumatology Research Institute, Amsterdam, Noord Holland, Netherlands
A Trial COmparing staNdard of Care Versus Treat to Target With telemonitoRing and Patient Education in Patients With Ulcerative cOlitis Initiating Adalimumab
- Conditions
- Interventions
- First Posted Date
- 2019-12-03
- Last Posted Date
- 2023-05-31
- Target Recruit Count
- 238
- Registration Number
- NCT04183608
- Locations
- 🇫🇷
CHRU de Besançon - Hôpital Jean Minjoz, Besançon, France
🇫🇷Centre hospitalier de Cholet, Cholet, Maine Et Loire, France
🇫🇷APHP - Hôpital du Kremlin-Bicêtre, Le Kremlin-Bicêtre, Île-de-France, France
ADalimumab in Persistent Early Oligoarthrits Study (ADEOS)
- Conditions
- Interventions
- First Posted Date
- 2019-11-07
- Last Posted Date
- 2019-11-07
- Lead Sponsor
- University of Leeds
- Target Recruit Count
- 22
- Registration Number
- NCT04154852
- Locations
- 🇬🇧
Leeds Teaching Hospitals NHS Trust, Leeds, West Yorkshire, United Kingdom
Precision Crohn's Disease Management Utilizing Predictive Protein Panels (ENvISION)
- First Posted Date
- 2019-10-18
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Target Recruit Count
- 239
- Registration Number
- NCT04131504
- Locations
- 🇺🇸
Medical College of Wisconsin, Milwaukee, Wisconsin, United States
🇺🇸Connecticut Children's Medical Center, Hartford, Connecticut, United States
🇺🇸Nationwide Children's Hospital, Columbus, Ohio, United States
Hidradenitis Suppurativa Patient Experience With Humira Treatment
- Conditions
- Interventions
- First Posted Date
- 2019-10-18
- Last Posted Date
- 2022-09-29
- Lead Sponsor
- Wake Forest University Health Sciences
- Registration Number
- NCT04132388
- Locations
- 🇺🇸
Wake Forest Health Sciences Dermatology, Winston-Salem, North Carolina, United States
Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy
- Conditions
- Interventions
- First Posted Date
- 2019-10-04
- Last Posted Date
- 2022-05-16
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 67
- Registration Number
- NCT04115748
- Locations
- 🇭🇺
Synexus (DRS) - Synexus Magyarorszag Kft. Budapest, Budapest, Hungary
🇵🇱Centrum Medyczne Pratia Gdynia, Gdynia, Poland
🇵🇱Medycyna Kliniczna Marzena Waszczak-Jeka, Warszawa, Poland
A Real-world Study of Imraldi® Use
- First Posted Date
- 2019-09-13
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Biogen
- Target Recruit Count
- 1000
- Registration Number
- NCT04089514
- Locations
- 🇬🇧
Research Site, Sussex, United Kingdom
A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis
- First Posted Date
- 2019-09-12
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 30
- Registration Number
- NCT04088409
- Locations
- 🇫🇷
Hôpitaux Universitaires Paris Sud - Hôpital Bicêtre, Le Kremlin Bicetre, France
🇫🇷Hôpital Universitaire Necker Enfants Malades, Paris, France
🇫🇷Centre Hospitalier Universitaire de Poitiers, Poitiers Cedex, France
Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease
- Conditions
- Interventions
- First Posted Date
- 2019-07-05
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- University of Michigan
- Target Recruit Count
- 7
- Registration Number
- NCT04009668
- Locations
- 🇺🇸
The University of Michigan, Ann Arbor, Michigan, United States
🇺🇸Levine Children's Hospital/Atrium Health, Charlotte, North Carolina, United States
🇺🇸New York University, New York, New York, United States
PK, Safety and Tolerability Study of AVT02 (Adalimumab) Pre-filled Syringe (PFS) vs, AVT02 Autoinjector (AI)
- First Posted Date
- 2019-06-12
- Last Posted Date
- 2022-05-04
- Lead Sponsor
- Alvotech Swiss AG
- Target Recruit Count
- 207
- Registration Number
- NCT03983876
- Locations
- 🇳🇿
Auckland Clinical Studies, Auckland, New Zealand
🇳🇿Christchurch Clinical Studies Trust Limited, Christchurch, Chistchurch, New Zealand
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.